Mithramycin for Lung, Esophagus, and Other Chest Cancers
Status:
Terminated
Trial end date:
2019-09-27
Target enrollment:
Participant gender:
Summary
Background:
- Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted
against some forms of cancer, but was never accepted as a treatment. Research suggests that
it may be useful against some cancers of the chest, such as lung and esophageal cancer or
mesothelioma. Researchers want to see if mithramycin can be used to treat these types of
cancer.
Objectives:
- To see if mithramycin is safe and effective against different chest cancers.
Eligibility:
- Individuals at least 18 years of age who have lung, esophagus, pleura, or mediastinum
cancers.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected. Imaging studies and tumor tissue samples will be used to
monitor the cancer before treatment.
- Participants will receive mithramycin every day for 7 days, followed by 7 days without
treatment. Each 14-day round of treatment is called a cycle.
- Treatment will be monitored with frequent blood tests and imaging studies.
- Participants will continue to take the drug for as long as the side effects are not
severe and the tumor responds to treatment.